<https://rdf.molmedb.upol.cz/reference/ref3785> <http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method33>,
		<https://identifiers.org/molmedb/MM492039>;
	<http://purl.org/ontology/bibo/pmid> "24900359"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM475675>;
	<http://purl.org/ontology/bibo/doi> "10.1021/ml2001196"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM493267>;
	<http://purl.org/dc/terms/bibliographicCitation> "Crosignani S, Jorand-Lebrun C, Page P, Campbell G, Colovray V, Missotten M, Humbert Y, Cleva C, Arrighi JF, Gaudet M, Johnson Z, Ferro P, Chollet A.: Optimization of the Central Core of Indolinone-Acetic Acid-Based CRTH2 (DP2) Receptor Antagonists. ACS Med Chem Lett, Volume 2 (8), 2011"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM493346>,
		<https://rdf.molmedb.upol.cz/interaction/membrane21> .
<https://rdf.molmedb.upol.cz/interaction/int1026809> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3785> .
<https://rdf.molmedb.upol.cz/interaction/int1030178> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3785> .
<https://rdf.molmedb.upol.cz/interaction/int1030309> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3785> .
<https://rdf.molmedb.upol.cz/interaction/int1026808> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3785> .